BridgeBio Pharma (NASDAQ:BBIO) Chairman Charles J. Homcy Sells 20,000 Shares of Stock

BridgeBio Pharma (NASDAQ:BBIO) Chairman Charles J. Homcy sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $36.00, for a total value of $720,000.00. Following the completion of the sale, the chairman now directly owns 1,342,291 shares in the company, valued at approximately $48,322,476. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Charles J. Homcy also recently made the following trade(s):

  • On Tuesday, January 14th, Charles J. Homcy sold 10,000 shares of BridgeBio Pharma stock. The stock was sold at an average price of $35.00, for a total value of $350,000.00.

Shares of BridgeBio Pharma stock opened at $34.05 on Friday. The company has a quick ratio of 14.00, a current ratio of 14.00 and a debt-to-equity ratio of 0.14. BridgeBio Pharma has a 12 month low of $17.61 and a 12 month high of $48.36. The business has a fifty day simple moving average of $34.71 and a 200 day simple moving average of $29.20.

Several institutional investors have recently made changes to their positions in BBIO. State Street Corp grew its stake in shares of BridgeBio Pharma by 129.9% during the fourth quarter. State Street Corp now owns 808,243 shares of the company’s stock worth $28,329,000 after purchasing an additional 456,605 shares during the period. TimesSquare Capital Management LLC grew its stake in shares of BridgeBio Pharma by 258.9% during the third quarter. TimesSquare Capital Management LLC now owns 538,330 shares of the company’s stock worth $11,558,000 after purchasing an additional 388,330 shares during the period. Vanguard Group Inc. acquired a new stake in shares of BridgeBio Pharma during the second quarter worth $2,354,000. BlackRock Inc. acquired a new stake in shares of BridgeBio Pharma during the second quarter worth $1,442,000. Finally, California Public Employees Retirement System acquired a new stake in shares of BridgeBio Pharma during the fourth quarter worth $1,315,000. 83.49% of the stock is owned by institutional investors and hedge funds.

BBIO has been the subject of several analyst reports. Raymond James raised their target price on BridgeBio Pharma from to in a research report on Tuesday, January 7th. Zacks Investment Research upgraded BridgeBio Pharma from a “sell” rating to a “hold” rating in a research report on Monday, January 6th. Piper Jaffray Companies dropped coverage on BridgeBio Pharma in a research note on Friday, October 18th. Finally, UBS Group began coverage on BridgeBio Pharma in a research note on Tuesday, December 3rd. They issued a “reduce” rating for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. BridgeBio Pharma presently has a consensus rating of “Buy” and an average target price of $40.63.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology.

Featured Article: How Do You Calculate Return on Equity (ROE)?

Insider Buying and Selling by Quarter for BridgeBio Pharma (NASDAQ:BBIO)

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.